Abstract
To complement the immunosuppression regimens, at the time the lung transplantation or early postoperative period many centers are using basiliximab as induction therapy which is an antibody antagonist of the Interleukin-2 receptor. It is known that infection is the main cause of death in the first month after lung transplantation, coinciding with the same period of greater dysfunction of …